Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.
The 2024 American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego on December 7-10. This year’s meeting provided groundbreaking scientific sessions, state-of-the-art clinical insights, and the latest advancements in hematology research and treatment. Among other conditions, the meeting offered new data on chronic myeloid leukemia (CML), including the tyrosine kinase inhibitor asciminib in the ASC4FIRST and ASC2ESCALATE trials, combination therapies, the safety and efficacy of imatinib in the TIPI study, novel agents, and the emerging role of genomic testing.
Lindsay A. Rein, MD
Assistant Professor, Department of Medicine, Duke University School of Medicine, Durham, North Carolina
“It will really be interesting to see how some of these discussions surrounding quality of life for patients and the cost of care for these medicines to positively impact patients really evolve over the course of the next year.”
Preconference Considerations
ASH 2024: Previewing Key Updates in CML
Dr Rein is excited to hear discussions surrounding updated data presented at the upcoming ASH meeting, particularly from the ASC4FIRST and ASC2ESCALATE trials regarding asciminib in the frontline and second-line settings. Additionally, Dr Rein is looking forward to new findings on novel agents such as TGRX-678 and HQP1351 and is also interested in combination therapies, data addressing long-term treatment side effects, strategies for treatment-free remission, and refining definitions of TKI failure or intolerance to improve patient management.
Quick Clinical Takeaways
ASH 2024: Key Highlights in the Treatment of CML
Dr Rein shares insights on new data regarding asciminib, which showed superior efficacy and safety in the ASC4FIRST trial following its recent approval. She emphasizes the ongoing need for novel treatments for patients who are intolerant of or refractory to current therapies and highlights the importance of clearly defining resistance and intolerance in CML. The meeting also featured discussions on patient-centered outcomes, such as quality of life and treatment costs, along with the challenges of managing advanced CML stages, including blast crisis.
How Will My Patients Benefit?
ASH 2024: Impact of New CML Treatments
Dr Rein comments on how the ASH 2024 meeting showcased the approval of asciminib for frontline and second-line CML treatment, offering new options for clinicians in managing the disease. The key clinical challenge is determining how best to integrate asciminib into treatment regimens, given its strong safety and efficacy data. Additionally, the evolving discussions on the cost of care and its impact on patient quality of life will be important as newer therapies are introduced alongside older, generic drugs.
Polling Question
Summary
The 2024 ASH Annual Meeting featured key advancements in CML treatment, including superior safety and efficacy data for asciminib from the ASC4FIRST and ASC2ESCALATE trials in frontline and second-line settings. Presentations also introduced novel agents such as TGRX-678 and HQP1351, combination therapies, and strategies for treatment-free remission while addressing long-term side effects, resistance, and advanced stages of CML, such as blast crisis. Discussions emphasized patient-centered outcomes, including quality of life and the financial impact of newer therapies. In a series of three videos, Dr Rein highlighted the importance of integrating asciminib into treatment regimens and the need for clearly defining resistance and intolerance to improve patient care.
Resources
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Conference MDAngle: ASH 2024Chronic Myeloid Leukemia - Medscape - Dec 27, 2024.
Comments